Join to View Full Profile
220 Massachusetts AveCambridge, MA 02139
Dr. Gill is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Johns Hopkins UniversityFellowship, Neuroimmunology & Multiple Sclerosis, 2021 - 2024
- University of Pennsylvania Health SystemResidency, Neurology, 2018 - 2021
- University of Pennsylvania Health SystemInternship, Internal Medicine, 2017 - 2018
- Perelman School of Medicine at the University of PennsylvaniaClass of 2017
- University of PennsylvaniaPhD, Neuroscience , 2011 - 2015
- Case Western Reserve UniversityB.S./B.S., Biochemistry/Biology , Summa Cum Laude, 2005 - 2009
Certifications & Licensure
- PA State Medical License 2022 - 2026
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Neuroscience Research Training Award American Academy of Neurology, 2023
- Best Platform Presentation Tykeson Fellows Conference, National Multple Sclerosis Society, 2022
- Dichter Translational Research Award University of Pennsylvania, Neurology Residency Program, 2021
- Join now to see all
Clinical Trials
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Start of enrollment: 2022 Aug 30
- Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis Start of enrollment: 2020 Jun 11
Publications & Presentations
PubMed
- NLRX1 limits inflammatory neurodegeneration in the anterior visual pathway.Alexander J Gill, Matthew D Smith, Danny Galleguillos, Thomas Garton, Jackson W Mace
Journal of Neuroinflammation. 2025-01-28 - 2 citationsNeurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.Carson M Quinn, Prashanth Rajarajan, Alexander J Gill, Hannah Kopinsky, Andrew B Wolf
Neurology. 2024-12-10 - 10 citationsNeurodegeneration and demyelination in multiple sclerosis.Thomas Garton, Sachin P Gadani, Alexander J Gill, Peter A Calabresi
Neuron. 2024-10-09
Journal Articles
- Retinal optical coherence tomography in MSSchorr EM, Gill AJ, Saidha S, Calabresi PA, Practical Neurology, 9/2022
Books/Book Chapters
Press Mentions
- An Interview with Alexander GillSeptember 9th, 2014
Grant Support
- Targeting NLRX1 to Limit Inflammatory Demyelination and NeurodegenerationAmerican Academy of Neurology2024–2026
- Autoantibodies and Neurologic Immune-Related Adverse Events in Immune Checkpoint Inhibitor TherapyPhysicians Scientist Training Program, Johns Hopkins University2022–2024
- Targeting Neurotoxic Inflammatory Glia and NLRX1 in MS/EAENational Multiple Sclerosis Society and the American Brain Foundation2021–2024
- Heme Oxygenase-1 as a novel therapeutic target in HIV-mediated neurodegenerationNational Institute of Mental Health (NIMH)2014–2017
- Training in HIV PathogenesisNational Institute of Allergy and Infectious Diseases (NIAID)2012–2014
Professional Memberships
- Member
- Consortium of Multiple Sclerosis CentersMember
- National Multiple Sclerosis SocietyMember
- American Neurological AssociationMember
External Links
- ResearchGatehttps://www.researchgate.net/profile/Alexander-Gill/research
- Google Scholarhttps://scholar.google.com/citations?user=HNlrOYYAAAAJ&hl=en
- LinkedInhttps://www.linkedin.com/in/alexander-gill-203288277/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: